3DHEALS Boston 2019 Summer Event: Healthcare 3D Printing and Bioprinting, Reconnecting Ecosystem  🗓

Category: Event
Jul 18, 2019
ical Google outlook Event

Come and join us at this octane annual summer networking event and learn from a world-class expert on cutting-edge technologies in healthcare 3D printing and bioprinting industry.

Location:

GE

33-41 Farnsworth Street

Boston, MA 02210

Agenda:

6:30-7:00 PM Registration/Networking

7:00-7:15 PM Sponsor/3DHEALS/Boston Community Manager Intro

7:15-7:25 PM Scott Rader (GE Healthcare) From hype to hope:  translating 3D printed promises to healthcare realities– A view from the trenches

7:25-7: 30 PM Q&A

7:30-7: 40 PM Kimberly Homan Kidney Tissue Regeneration and Bioprinting

7:40-7:45 PM Q&A

7:45-7:55 PM Richard McFarland, M.D., Ph.D. (ARMI, USA) Bioprinting: The Panacea or yet another Pandora’s Box for Regenerative Medicine?

7:55-8:00 PM Q&A

8:00-8:10 PM Al Ranger (Ranger Labs, NH, USA) 3D Printing for Dental Labs

8:10-8:15 PM Q&A

8:15-8:45 PM Panel Q&A

8:45-9:30 PM Networking and wrap-up

(After event location will be announced to continue the conversations.)


Confirmed speakers:

Kimberly Homan, Ph.D.

Kimberly Homan just moved from being a Research Associate at the Wyss Institute for Biologically Inspired Engineering at Harvard to a position in a stealth-mode startup company. She started her scientific career at the University of Arizona where she earned a chemical engineering degree. She then took a break from science and was commissioned a logistics officer in the United States Marine Corps where she served for 6 years. After her service, she attended the University of Texas at Austin where she earned a Ph.D. in biomedical engineering. While in Austin, Texas she started a company based on the biomedical imaging contrast agents she developed in her graduate work. Her company, NanoHybrids Inc, is still based in Austin and has brought several lines of unique gold nanoparticles to market. Kimberly then applied her biomedical engineering expertise to tissue engineering and worked for the last 6 years to use 3D bioprinting to create functional living tissues. In the laboratory of Jennifer Lewis at Harvard University in Wyss and in collaboration with Annie Moisan at Roche, she built kidney tissue on perfusable chips that can be used for drug screening, mechanistic safety, and ultimately, regenerative medicine.


Richard D. McFarland, Ph.D., M. D., Chief Regulatory Officer, ARMI

Richard McFarland, PhD, MD joins ARMI as its Chief Regulatory Officer effective May 1, 2017.  Dr. McFarland comes to ARMI from the Food and Drug Administration’s Center for Biologics Evaluation and Research (FDA/CBER) where his career spanning 16 years involved review over an extensive range of products and policy development in numerous areas both inside FDA, across the federal government, and internationally. He spent more than a decade as Associate Director of Policy for FDA/CBER’s Office of Tissues and Advanced Therapies and its predecessor office, the Office of Cellular, Tissue and Gene Therapies. In this position, he was heavily involved in policy development for tissue engineering, regenerative medicine, and alternatives to animal use in regulatory decision making. In addition to development of risk-based regulatory oversight paradigms within FDA, his interests included broader efforts to create an interlocking network of interagency efforts to foster growth of basic and translational science to support maturation of the overlapping fields of tissue engineering and regenerative medicine from primarily discovery science toward a stage of commercial development.

His position at ARMI will allow him to apply the knowledge and experiences gained by over the last decade and half in the field to ARMI’s efforts to establish an industrial common, in the form of a Manufacturing Innovation Institute within the Manufacturing USA network, with the aims to coalesce the field and provide a route for nascent product concepts to reach the marketplace. Bringing these products to the market will benefit critical U.S. public health needs and will provide the economic drivers needed to create new highly-skilled jobs.

Dr. McFarland, Ph.D., M. D. received his B.S., Ph.D., and M.D. from the University of North Carolina at Chapel Hill, and completed his anatomic/clinical pathology residency and immunopathology fellowship training at UT Southwestern in Dallas. Immediately prior to joining the FDA, he was on the faculty of the Pathology Department of the University of Texas Southwestern in Dallas.  In addition to FDA policy documents he has co-authored over 25 articles in peer-reviewed articles journals including Nature, the Proceedings of the National Academy of Science (PNAS), and Blood.

Talk Title:

Bioprinting: The Panacea or yet another Pandora’s Box for Regenerative Medicine?


Scott Rader, Ph.D., GM Additive Manufacturing at GE Healthcare

Scott Rader is an accomplished medical device executive with a consistent record of achievement spanning multiple areas of clinical product focus. Broad functional expertise in product development, team building, entrepreneurship, marketing and business development. A decisive entrepreneur with practical experience bringing products to market, building IP portfolios (holds fourteen patents), raising venture capital and championing product development. 

Talk Title: From hype to hope:  translating 3D printed promises to healthcare realities– A view from the trenches

Pitching Companies:

Related Articles:

3DHEALS Boston 2018 Recap: From Cleft Palate to Bioprinted Lungs, Reality, Dreams, and Ambition

Related Events:

3DHEALS/CMIT 2019: Entrepreneurship and Commercialization workshop during CMIT, UCLA, 2019

Comments